Skip to Content
Merck
CN

HCMBMAG-22K

MILLIPLEX® Human Cancer/ Metastasis Biomarker Panel 9-Plex

Configurable Human Cancer/Metastasis Biomarker 9-Plex Panel

Sign In to View Organizational & Contract Pricing.

About This Item

UNSPSC Code:
12161503
NACRES:
NA.84
eCl@ss:
32161000

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

MILLIPLEX® Human Cancer/ Metastasis Biomarker Panel 9-Plex, Configurable Human Cancer/Metastasis Biomarker 9-Plex Panel

species reactivity

human

Quality Level

200

assay range

accuracy: 70-105%, standard curve range: 0,019-80 ng/mL
(TRAP5), standard curve range: 0,048-20 ng/mL
(YKL40), standard curve range: 0.002-10 ng/mL
(GDF15), standard curve range: 0.007-30 ng/mL
(DKK-1), standard curve range: 0.007-30 ng/mL
(OPG), standard curve range: 0.036-150 ng/mL
(NSE), standard curve range: 0.195-800 ng/mL
(Periostin), standard curve range: 0.976-4,00 0 ng/mL
(Osteonectin (SPARC)), inter-assay cv: <16%
intra-assay cv: <10%

technique(s)

multiplexing: suitable

input

serum plasma (Cell culture, cell culture supernatants)

packaging

pkg of 1 ea

manufacturer/tradename

Milliplex®

detection method

fluorometric (Luminex® xMAP® technology)

shipped in

wet ice

storage temp.

2-8°C

Related Categories

General description

Metastasis is a complex process in which tumor cells leave the primary tumor site and migrate to other parts of the body via blood and lymph vessels or by tumor invasion of surrounding tissues and organs. Breaking away from the primary tumor, cancer cells attach to and degrade extracellular matrix proteins that separate tumor from surrounding tissues to escape into the stroma. Where metastases form often depends on the primary tumor. Bone metastases, for example, tend to arise from breast, prostate and kidney tumors. This organ/tissue specificity seems to involve chemical signals from both chemokines and growth factors.

Application

MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 9 analytes in human serum, plasma, tissue/cell culture supernatants or lysate samples.

Analytes included: DKK-1, GDF-15, Neuron-specific Enolase (NSE), Osteonectin (SPARC), Osteoprotegerin (OPG), Periostin, TRAP5, TWEAK, YKL40 (CHI3L1)

Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.

Features and Benefits

  • Comprehensive Biomarker Detection: The panel includes nine key metastasis biomarkers (DKK-1, GDF-15, NSE, Osteonectin, OPG, Periostin, TRAP5, TWEAK, YKL40) relevant to various tumor types.
  • Multiplex Detection Capability: Utilizes the Luminex®xMAP® platform in bead format to enable simultaneous quantitative analysis of multiple biomarkers, enhancing throughput and efficiency.
  • Flexible Sample Types: Compatible with human serum, plasma, and tissue/cell culture supernatants or lysates, providing versatility in sample collection.
  • Configurable Kit Design: Researchers can design their multiplex kit by selecting analytes tailored to their specific research needs.
  • Facilitates Understanding of Metastatic Mechanisms: By providing insights into the biomarkers associated with metastasis, the panel aids in understanding the complex processes of tumor cell migration and organ specificity.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

For research use only. Not for use in diagnostic procedures.

Label License/Sticker for Assay Product:

By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

target_organs

Respiratory Tract

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

Regulatory Information

新产品
This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Paul G Corn et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 26(5), 990-999 (2020-01-17)
Cabozantinib, an oral inhibitor of c-MET/VEGFR2 signaling, improved progression-free survival (mPFS) but not overall survival (OS) in metastatic castrate-resistant prostate cancer. We evaluated cabozantinib plus androgen deprivation therapy (ADT) in hormone-naïve metastatic prostate cancer (HNMPCa). Patients received ADT plus cabozantinib
R H Brophy et al.
Osteoarthritis and cartilage, 27(12), 1778-1789 (2019-08-21)
Emerging evidence suggests that injury to the anterior cruciate ligament (ACL) typically initiates biological changes that contribute to the development of osteoarthritis (OA). The molecular biomarkers or mediators of these biological events remain unknown. The goal of this exploratory study
Alison Crichton et al.
Journal of neurotrauma, 38(8), 1151-1163 (2019-12-28)
Despite many children experiencing fatigue after childhood brain injury, little is known about the predictors of this complaint. To date, traditional indices of traumatic brain injury (TBI) severity have not predicted reliably persisting fatigue (up to three years post-injury). This

Related Content

Multiplex Cancer Assays for Cancer Research| MILLIPLEX® Assays

Cancer biomarker detection through MILLIPLEX® multiplex cancer assays can accelerate studies of tumorigenic processes helping advance cancer research.

Protocol- HCMBMAG-22K
Quality Control Range Sheet- HCMB-119 and HCMB-219
Quality Control Ranges: Human Cancer Metastasis Biomarker Magnetic Bead Panel
See All

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service